Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared updates ...

Unfortunately, shareholders of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have suffered share price declines over the last year. To wit the share price is down 54% in that time. To make matters worse, ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics (NASDAQ:SRPT) stock draws an Overweight rating at Wells Fargo, based on commercial prospects for ...

Sarepta (SRPT) shared updates from its clinical programs focused on limb-girdle muscular dystrophy subtypes 2C/R5, 2D/R3, and 2E/R4. Following ...

Fintel reports that on April 11, 2025, Wells Fargo initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety ...

Sarepta and Roche announced a 16-year-old US patient dosed with Elevidys died of acute liver failure in March 2025.

One day after the European Medicines Agency requested that three clinical trials of Elevidys be placed on hold after the ...

Wells Fargo launched its coverage of Sarepta Therapeutics (NASDAQ:SRPT) with an Overweight recommendation, citing commercial prospects for Elevidys, a gene therapy developed by SRPT with Roche ...

Multidisciplinary coordination across prescribing teams, nursing, laboratory medicine, finance, and infusion centers is crucial for gene therapy delivery in Duchenne muscular dystrophy (DMD).